New FDA Validator Rules V1.6 Explained
In this blog, we explore what you need to know about the update to the…
CertaraJanuary 12, 2023
Simcyp Secondary Intelligence Software
Introducing Secondary Intelligence. The first and only evidence based quantitative technology for managing off target…
CertaraJanuary 10, 2023
Certara Awarded NIH Contract for Toxicology Consulting Support
Certara toxicology experts to support NIH’s BPN and HEAL drug development programs for nervous system…
CertaraJanuary 10, 2023
Ghent University wins the 2021/22 Certara-Simcyp Grant and Partnership Scheme
PRINCETON, N.J., January 9, 2023 — Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation,…
CertaraJanuary 9, 2023
Certara Acquires Vyasa, an Artificial Intelligence Company that Delivers Predictions to Accelerate Scientific Innovation
Certara improves software capabilities by expanding into deep learning and data fabric PRINCETON, N.J.— January…
CertaraJanuary 4, 2023
New FDA Requirement to Support Labeling on DDIs in the Pediatric Population
The effects of drug-drug interactions (DDIs) could differ in the pediatric population compared to adults.…
CertaraDecember 21, 2022
The Phoenix Workflow Shortcuts Every Pharmacokineticist Needs
Certara’s Phoenix™ Pharmacokinetic and Pharmacodynamic (PK/PD) Platform can revolutionize your pharmaceutical organization’s approach to PK/PD…
CertaraDecember 16, 2022
Certara Announces the Completion of Arsenal Capital Partners’ Investment and the Appointment of David Spaight to the Board of Directors
Arsenal closed the previously announced $449M stock purchase from funds controlled by EQT Private Equity…
CertaraDecember 8, 2022
